Statin therapy-evidence beyond lipid lowering contributing to plaque stability.
Primarily statin drugs inhibit hepatic 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase, which is responsible for the reduction in circulating low-density lipoprotein (LDL) cholesterol. Several findings from recent research studies indicate that statins have multiple actions that favorably influence key factors involved in the atherogenic process. These so-called pleiotropic properties affect various aspects of cell function, inflammation, coagulation, and vasomotor activity. These effects are mediated either indirectly through LDL cholesterol reduction or via a direct effect on cellular functions. Such actions may contribute to the early cardiovascular benefit observed in several outcome trials with statin drugs therapy. Although many of the pleiotropic properties of statins may be a class effect, some may be unique to certain agents and account for differences in their pharmacological activity. This review summarise the results of the major outcome trials of statins and non-statins therapy and the possible mechanisms beyond lipid lowering contributing to plaque stability.
de Lorenzo
Ferruccio
F
Thrombosis Research Institute, Genomics & Atherothrombosis, London, UK. dlorenzo@tri-london.ac.uk
Feher
Michael
M
Martin
Juliette
J
Collot-Teixeira
Sophie
S
Dotsenko
Olena
O
McGregor
John Louis
JL
D001161:Arteriosclerosis / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors